title: Validity of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for pretreatment evaluation of patients with cervical carcinoma: a retrospective pathology-matched study.
abstract: OBJECTIVE
  The aim of this study was to evaluate the validity of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) for pretreatment evaluation of patients with cervical carcinoma.
  
  
  METHODS
  Retrospective evaluation of 63 patients, diagnosed with stage IA-IIA cervical carcinoma who underwent 18F-FDG PET/CT before surgery, was performed. Sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios (LRs) of PET/CT for predicting the positive cervix, vagina, uterine body, and lymph node invasion at the surgical specimen was calculated.
  
  
  RESULTS
  Sensitivity, specificity, positive predictive value, and negative predictive value of the positive cervix invasion in PET/CT to detect positive surgical specimen were 88.2%, 75%, 93.8%, and 60%, respectively. The LR+ ratio was 3.5, and the LR- ratio was 0.2. Sensitivity, specificity, positive predictive value, and negative predictive value of the positive vagina invasion in PET/CT to detect positive surgical specimen were 100%, 70.97%, 5.3%, and 100%, respectively. The LR+ ratio was 3.4, and the LR- ratio was 0. Sensitivity, specificity, positive predictive value, and negative predictive value of the positive uterine body invasion in PET/CT to detect positive surgical specimen were 75%, 83.1%, 23.1%, and 98%, respectively. The LR+ ratio was 4.4, and the LR- ratio was 0.3. Sensitivity, specificity, positive predictive value, and negative predictive value of the positive lymph node invasion in PET/CT to detect positive surgical specimen were 87.5%, 78.4%, 38.9%, and 97.6%, respectively. The LR+ ratio was 4.1, and the LR- ratio was 0.2.
  
  
  CONCLUSIONS
  The cervix invasion, negative uterine body invasion, and negative lymph node invasion are effective 18F-FDG PET/CT findings.
authors.affiliation: *Department of Obstetrics and Gynecology, Shanghai First People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China; †Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital, Shanghai, China; and ‡Department of Obstetrics and Gynecology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Dong
authors.forename: Xiaoyun
authors.initials: X
authors.lastname: Wang
authors.forename: Yanan
authors.initials: Y
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Jiawen
authors.initials: J
authors.lastname: Zhang
authors.forename: Wenyan
authors.initials: W
authors.lastname: Qian
authors.forename: Sufang
authors.initials: S
authors.lastname: Wu
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed / Q000379:methods*; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000601:surgery
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18